Satyadeeptha Pharmaceuticals Limited

Brickwork Ratings assigns the ratings for the Bank Loan Facilities of Rs. 74.46 Crs. of Satyadeeptha Pharmaceuticals Limited

Particulars

Facilities**	Amount(Rs.Crs.)	Tenure	Rating#
Fund Based	64.46	Long Term	BWR BBB - /Stable Assignment
	(36.00)	Short Term	BWR A3 Assignment
Non Fund Based	10.00	Short Term	BWR A3 Assignment
	(9.00)
	(2.00)
	(5.00)
Grand Total	74.46	(Rupees Seventy Four Crores and Forty Six lakhs Only)

#Please refer to BWR website www.brickworkratings.com for definition of the ratings
**Details of Bank Loan facilities,consolidation or instruments are provided in Annexure RATING ACTION / OUTLOOK

Brickwork Ratings assigns the long term rating of "BWR BBB-/Stable" and the short term rating of "BWR A3" for the Bank Loan Facilities of Rs. 74.46 Crs. of Satyadeeptha Pharmaceuticals Limited

The ratings are positively influenced by the management's extensive chemical expertise and strategic product diversification into high-margin non-ARV therapeutics. The ratings are constrained by high vulnerability to strict environmental regulatory actions and a severe geographic concentration in raw material imports.

The ‘Stable’ outlook indicates a low likelihood of rating change over the medium term. BWR believes Satyadeeptha Pharmaceuticals Limited's business risk profile will be maintained over the medium term. The outlook may be revised to Positive if a sustained increase in the scale of operations and higher than envisaged profitability result in an improved financial risk profile and better gearing and debt protection metrics. The outlook may be revised to Negative if lower-than-expected revenue or profitability, a stretch in the working capital cycle, unanticipated capex or weakening gearing impact the financial risk profile.

KEY RATING DRIVERS

Credit Strengths:

• Experienced Core Management Team :

  The company is anchored by a technically proficient and highly experienced management team, led by promoters Dr. S. Ramakrishna and Dr. S. Janardhan Rao, who possess nearly three decades of specialized chemical and operational expertise in organic chemistry and bulk drug manufacturing. This stable corporate leadership is further reinforced by the strategic integration of younger whole-time directors into its senior management structure to systematically smooth over future succession and strengthen long-term operational continuity.

• Strategic Therapeutic Product Diversification :

  The company is successfully executing a strategic shift to reduce its historical dependence on Antiretroviral (ARV) therapeutics by actively diversifying into high-margin, high-growth non-ARV therapeutic segments. Satyadeeptha has expanded its commercial product portfolio to include advanced molecules targeting chronic conditions, such as Resmetirom (NASH/liver disease), Duloxetine (neurology/anti-depressant), and Ticagrelor (cardiology). This transition enables the company to tap into high-value domestic and international formulation markets, improving overall blended average selling prices and driving operating margins upward. By diversifying into multiple therapeutic areas, the company effectively mitigates product obsolescence risks and insulates its top-line revenue from price erosions or shifting procurement patterns in global ARV tender programs. This expanding product footprint strengthens the company’s business risk profile, enhancing market competitiveness and ensuring sustainable cash generation across diverse product life cycles.

Credit Risks:

• High Regulatory Operational Exposure :

  Operating within the heavily scrutinized bulk drug and chemical intermediate sector exposes the company to extreme regulatory and environmental compliance risks. This vulnerability was highlighted by a temporary plant shutdown directed by state authorities in FY25. Even though the manufacturing facility actively implements strict zero liquid discharge (ZLD) mechanisms and maintains comprehensive environmental compliance benchmarks, sudden politically or environmentally driven regulatory interventions can instantly halt manufacturing lines. Such unexpected pauses create massive supply-chain backlogs, cause immediate revenue contractions, and compress the cash accruals required for timely debt service obligations. Because mid-sized standalone entities possess thin liquidity buffers to absorb long operational suspensions, any renewed regulatory friction or adverse directive from environmental boards poses a persistent threat to production schedules, customer retention timelines, and overall credit profile stability.

• Severe Geographic Sourcing Concentration :

  Satyadeeptha faces intense supply chain vulnerabilities due to its high geographic dependency on raw material imports. The company relies extensively on its top five vendors based in China to supply approximately 77% of its critical raw materials and advanced chemical building blocks. This extreme structural concentration leaves its standalone operating profit margins highly exposed to sudden international border restrictions, regulatory changes in mainland China, global shipping spikes, or foreign exchange rate volatility. Because the company operates with limited bargaining power relative to massive global chemical suppliers, sudden input price hikes trigger immediate margin compression before cost increases can be successfully passed down to contractual formulation clients. While management enforces dual-sourcing protocols, the high dependence on a single geographic hub remains a structural weakness that dampens financial predictability during macroeconomic shocks.

ANALYTICAL APPROACH - Standalone

To arrive at its ratings, BWR has considered a standalone approach. Reference may be made to the Rating Criteria hyperlinked below.

RATING SENSITIVITIES

Moving ahead, the company's ability to expand its operational scale, boost profitability, and enhance liquidity and credit standing, along with the recent government policies affecting the sector, will be critical factors influencing its rating.

Positive Factors:-

• Total Operating Income sustaining above Rs 290.00 crore alongside an OPBDIT margin exceeding 14.00%.

• Improvement of the working capital cycle.

Negative factors:-

• Total Operating Income dropping below Rs 130.00 crore or OPBDIT margin falling below 8.00%.

• Progressive extension of the working capital cycle.

LIQUIDITY INDICATORS - Adequate

Adequate liquidity characterized by a sufficient cushion in accruals vis-a-vis repayment obligations and a moderate cash balance. No capex is envisaged for the near future. Its bank limits are utilized to the extent of 90% - 95% and is supported by the above unity current ratio.
The company maintains adequate liquidity to comfortably service its debt obligations. 
 

ABOUT THE ENTITY

Incorporated on June 23, 1993, Satyadeeptha Pharmaceuticals Limited is a prominent, research-driven active pharmaceutical ingredient manufacturer headquartered in Hyderabad, Telangana, with core manufacturing facilities operating out of Humnabad, Karnataka. The company's executive leadership is driven by its founder, Chairman and Managing Director Dr. Surapaneni Ramakrishna, alongside Executive Director Surapaneni Sarojini Devi and Chief Operating Officer Dr. S. Janardhana Rao. Satyadeeptha specializes in high-volume chemical synthesis operations, maintaining a massive 500 KL reaction infrastructure dedicated to producing global second and third-generation Antiretroviral (ARV) APIs and complex advanced intermediates, alongside newer cardiological and anti-diabetic drug segments.

ESG Profile

The company demonstrates an Adequate ESG profile based on its environmental, social, and governance practices.

Environmental: Environmental risks are driven by high water usage, waste generation, and reliance on energy-intensive processes, making disclosures on water consumption, waste-management practices, renewable energy share, and emissions levels particularly important. To address water consumption, the company operates a Zero Liquid Discharge (ZLD) facility that ensures the complete treatment and reuse of wastewater. Its waste-management practices are anchored by solvent recovery and reuse protocols that minimize waste generation and raw material consumption, supported by a Multi-Effect Evaporator (MEE) with a stripper system for efficient effluent treatment and emission control. For its renewable energy share, the company runs a 5 MW captive solar plant with plans to expand its capacity to 10 MW at the Chittiguppa facility to support higher production while lowering carbon footprints and energy costs. Its emissions levels are tightly controlled, with the company conducting annual monitoring of greenhouse gas (GHG) emissions (Scope 1 & 2) under an environmental management framework aligned with ISO 14001 principles and verified by periodic audits.

Social: Social factors hinge on adherence to labour laws, accident prevention frameworks, and human-capital development, with metrics such as workforce mix (% male, % female), safety performance, and training initiatives offering insights into operational resilience. While exact quantitative percentage breakdowns for its workforce mix are tracked through internal metrics to continuously enhance diversity, the company actively promotes fair employment practices and continuous employee skill development. The company's accident prevention frameworks and overall safety performance follow ISO 45001 principles, featuring regular monitoring of safety outcomes to minimize workplace hazards. Its welfare and training initiatives prioritize employee health and safety through the provision of Personal Protective Equipment (PPE), structured safety training, health camps, periodic medical check-ups, and health insurance coverage. Beyond internal operations, the company fulfills its broader social responsibilities by supporting local communities through the installation of borewells, plantation drives, public sanitation facilities, school sports infrastructure, and old-age home development.

Governance: Governance assessment focuses on board independence, committee effectiveness, and robustness of compliance systems, supported by readily available disclosures on board structure, audit mechanisms, and risk-management practices. The company's board structure incorporates formal, board-level oversight of ESG, compliance, risk management, and health & safety matters, with targets and progress reviewed quarterly by management and the Board to implement corrective actions. Its audit mechanisms and compliance systems are maintained via a strong Code of Conduct covering anti-bribery, ethics, data privacy, and regulatory compliance, alongside a transparent whistleblower mechanism featuring direct Audit Committee oversight and a zero-retaliation policy. Furthermore, the company’s risk-management practices are highly structured, integrating ESG and climate risks directly into its enterprise risk management framework, complemented by a Supplier Code of Conduct and due diligence processes to guarantee responsible sourcing and ethical compliance across its supply chain.

KEY FINANCIAL INDICATORS (Standalone)

Key Parameters	Units	FY 23 - 24 (Audited)	FY 24 - 25 (Audited)	FY 25 - 26 (Provisional)
Operating Revenue	Rs.Crs.	200.06	137.80	203.25
EBITDA	Rs.Crs.	18.30	12.88	28.11
PAT	Rs.Crs.	3.40	-0.76	7.19
Tangible Net Worth	Rs.Crs.	83.61	82.85	89.97
Total Debt / Tangible Net Worth	Times	0.85	1.13	1.04
Current Ratio	Times	1.01	1.01	1.09

KEY COVENANTS OF THE FACILITY RATED

The key covenants are the standard terms as stipulated in the sanction letters of the rated facilities.

STATUS OF NON-COOPERATION WITH PREVIOUS CRA

Not Applicable

RATING HISTORY FOR LAST THREE YEARS (including withdrawal and suspended)

Facilities	Current Rating  (2026)			2025		2024		2023
Type	Tenure	Amount (Rs.Crs.)	Rating	Date	Rating	Date	Rating	Date	Rating
Fund Based	LT	64.46	BWR BBB-/Stable (Assignment)	NA	NA	NA	NA	NA	NA
FB SubLimit	ST	(36.00)	BWR A3 (Assignment)	NA	NA	NA	NA	NA	NA
Non Fund Based	ST	10.00	BWR A3 (Assignment)	NA	NA	NA	NA	NA	NA
NFB SubLimit	ST	(9.00)	BWR A3 (Assignment)	NA	NA	NA	NA	NA	NA
		(2.00)	BWR A3 (Assignment)	NA	NA	NA	NA	NA	NA
		(5.00)	BWR A3 (Assignment)	NA	NA	NA	NA	NA	NA
Grand Total		74.46	(Rupees Seventy Four Crores and Forty Six lakhs Only)

Hyperlink/Reference to applicable Criteria

• General Criteria
• Approach to Financial Ratios
• Short Term Debt
• Manufacturing Company

Analytical Contacts
Varsha Jasmin Rating Analyst varsha.j@brickworkratings.com	Nagaraj K Director - Ratings Board : +91 80 4040 9940 nagaraj.ks@brickworkratings.com
Media Contact | media@brickworkratings.com	Client Support | clientsupport@brickworkratings.com

SL.No.	Name of the Bank/Lender	Type Of Facilities	Long Term(Rs.Crs.)	Short Term(Rs.Crs.)	Total(Rs.Crs.)	Complexity of the Instrument
1	Canara Bank	Term Loan - Out-standing	1.26	_	1.26	Simple##
2	Canara Bank	Cash Credit - Sanctioned	20.00	_	20.00	Simple##
3	Canara Bank	ILC/FLC - Sanctioned	_	10.00	10.00	Simple##
	Sub-Limit (Bank Guarantee (BG)) - Sanctioned		(2.00)
	Sub-Limit (Clean LC) - Sanctioned		(5.00)
4	HDFC Bank	Cash Credit - Sanctioned	36.00	_	36.00	Simple##
	Sub-Limit (Letter of Credit (ILC/FLC)) - Sanctioned		(9.00)
	Sub-Limit (Working Capital Demand Loan) - Sanctioned		(36.00)
5	HDFC Bank	Term Loan - Out-standing	4.16	_	4.16	Simple##
6	HDFC Bank	Term Loan - Out-standing	1.56	_	1.56	Simple##
7	HDFC Bank	Term Loan - Out-standing	0.48	_	0.48	Simple##
8	HDFC Bank	Term Loan - Out-standing	1.00	_	1.00	Simple##
Total			64.46	10.00	74.46
TOTAL (Rupees Seventy Four Crores and Forty Six lakhs Only)

## BWR complexity levels are meant for educating investors. The BWR complexity levels are available at www.brickworkratings.com / download / ComplexityLevels.pdf. Investors queries can be sent to info@brickworkratings.com.